Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 12:14:1033-1039.
doi: 10.2147/RMHP.S219294. eCollection 2021.

Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?

Navneet Arora  1 , Lokhesh C Anbalagan  1 , Ashok K Pannu  1
Affiliations
Review

Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?

Navneet Arora et al. Risk Manag Healthc Policy. .

Abstract

Background: Recent advances in mosquito eradication and antimalarial treatments have reduced the malaria burden only modestly. An effective malaria vaccine remains a high priority, but its development has several challenges. Among many potential candidates, the RTS,S/AS01 vaccine (MosquirixTM) remains the leading candidate.

Objective and method: This review aims to understand the advances in the RTS,S/AS01 vaccine, and future comments regarding the vaccine's effectiveness in malaria eradication. Literature review for the past five decades was performed searching PubMed, EMBASE Ovid, and Cochrane Library, with using the following search items: ("malaria" OR "WHO's malaria" OR "Plasmodium falciparum" OR "RTS,S" OR "RTS,S/AS01" OR "RTS,S/AS02" OR "pre-erythrocytic malaria" OR "circumsporozoite" OR "Mosquirix") AND ("vaccine" OR "vaccination").

Results: RTS,S/AS01, a recombinant pre-erythrocytic vaccine containing Plasmodium falciparum surface-protein (circumsporozoite) antigen, is safe, well-tolerated, and immunogenic in children. Three doses, along with a booster, have a modest efficacy of about 36% in children (age 5-17 months) and about 26% in infants (age 6-12 weeks) against clinical malaria during a 48-month follow-up. However, the efficacy varies among population subgroups and with the parasite strain, it reduces without a booster and offers protection for a limited duration. Because of its potential cost-effectiveness and positive public health effect, the vaccine is being investigated in a pilot program for mortality benefits and broader deployment.

Conclusion: The RTS,S/AS01 vaccine prevents malaria; however, it should be considered another addition to the malaria-control program and not as an eradication tool because of its relatively low to modest efficacy.

Keywords: RTS‚S; RTS‚S/AS01; WHO; circumsporozoite; malaria; pre-erythrocytic; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Major events in the progress of RTS,S/AS01 vaccine.
See this image and copyright information in PMC

References

    1. World Health Organization. World Malaria Report 2019. Geneva: WHO; 2019.
    1. Pannu AK. Malaria today: advances in management and control. Trop Doct. 2019;49(3):160–164. doi: 10.1177/0049475519846382 - DOI - PubMed
    1. Quispe AM, Pozo E, Guerrero E, et al. Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria? Am J Trop Med Hyg. 2014;91:11–17. doi: 10.4269/ajtmh.12-0610 - DOI - PMC - PubMed
    1. Penny MA, Verity R, Bever CA, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387:367–375. doi: 10.1016/S0140-6736(15)00725-4 - DOI - PMC - PubMed
    1. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020;5:48. doi: 10.1038/s41541-020-0196-3 - DOI - PMC - PubMed

LinkOut - more resources